Related Experiment Video
Updated: Apr 27, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
38.4K
New and emerging therapies in psoriasis
Craig L Leonardi1, Kenneth B Gordon2
1Clinical Professor of Dermatology, Saint Louis University, Central Dermatology, St Louis, Missouri.
Seminars in Cutaneous Medicine and Surgery
|July 1, 2014
Summary
This article reviews cytokine inhibitors for psoriasis, including ustekinumab targeting IL-12/IL-23. It also covers emerging therapies like IL-17 and IL-23 inhibitors, and small-molecule kinase inhibitors.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Cytokine pathways, including IL-12, IL-23, and IL-17, play critical roles in psoriasis pathogenesis.
- Targeting these pathways offers therapeutic potential.
Purpose of the Study:
- To discuss the scientific rationale for using cytokine inhibitors in psoriasis treatment.
- To review efficacy and safety data of approved and emerging therapies.
- To highlight novel therapeutic targets in psoriasis.
Main Methods:
- Literature review of scientific rationale, efficacy, and safety data.
- Discussion of specific drugs targeting cytokine pathways.
- Analysis of small-molecule kinase inhibitors.
Main Results:
- Ustekinumab, an IL-12/IL-23 inhibitor, demonstrates efficacy in psoriasis.
- Emerging therapies include IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) and an IL-23 blocker (tildrakizumab).
- Small-molecule inhibitors like apremilast (PDE4) and tofacitinib (JAK) also show promise.
Conclusions:
- Cytokine inhibitors represent a significant advancement in psoriasis management.
- Targeting specific cytokine pathways offers tailored treatment options.
- Ongoing research continues to expand therapeutic strategies for psoriasis.
Related Concept Videos
01:27Acne Infection
91
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
91
01:19Clinical Applications of Epidermal Stem Cells
2.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
01:21EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K